Longtime CFO Ruth Porat is remaining with the company ... This story was originally featured on Fortune.com An Eli Lilly and Company veteran is heading to Alphabet Inc. to become the next finance ...

Eli Lilly (LLY) shares were down slightly Tuesday despite reporting better-than-expected earnings on both the top and bottom lines for the final quarter of 2023, driven by an expected boost from ...

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it "checked all the boxes." ...

Anat Ashkenazi, previously senior vice president, controller and chief financial officer of Lilly Research Laboratories, has been named as his successor and will now be the next CFO. Ashkenazi joined ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

The U.K. biotechnology company Thursday said Travis Coy has been appointed CFO and head of corporate ... and mergers and acquisitions at Eli Lilly. He has served as non-executive director of ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.